Mosaic ImmunoEngineering (CPMV) Operating Expenses (2010 - 2026)
Mosaic ImmunoEngineering (CPMV) posted quarterly Operating Expenses of $154802.0 for Q1 2026, down 11.43% year-over-year from $174774.0 in Q1 2025, and up 4.5% quarter-over-quarter from $148133.0 in Q4 2025.
Mosaic ImmunoEngineering (CPMV) Operating Expenses (2010 - 2026) Analysis & Trends
Mosaic ImmunoEngineering's Operating Expenses history runs 17 years deep, the most recent figure standing at $154802.0 for Q1 2026.
- In Q1 2026, Operating Expenses fell 11.43% year-over-year to $154802.0; the TTM figure through Mar 2026 stood at $596147.0 (down 24.12% YoY), while the FY2025 annual figure was $616119.0, down 29.96% from the prior year.
- Operating Expenses for Q1 2026 stood at $154802.0, up from $148133.0 in the prior quarter.
- The five-year high for Operating Expenses was $883726.0 in Q2 2022, with the low at $18082.0 in Q1 2023.
- The 5-year median for Operating Expenses is $186430.0 (2024), against an average of $278673.7.
- Peak annual rise in Operating Expenses reached 1587.25% in 2023, while the deepest fall reached 97.52% in 2023.
- Mosaic ImmunoEngineering's Operating Expenses stood at $497554.0 in 2022, then slumped by 44.61% to $275618.0 in 2023, then plunged by 45.52% to $150157.0 in 2024, then slipped by 1.35% to $148133.0 in 2025, then gained by 4.5% to $154802.0 in 2026.
- Business Quant data shows CPMV's Operating Expenses at $154802.0 in Q1 2026, $148133.0 in Q4 2025, and $144358.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.06 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 427.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 541.02 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -784.57 Mn |
| 10 | Mosaic ImmunoEngineering | 527,536.97 | 527,536.97 | - | 154,802.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 154,802.00 |
| Dec 31, 2025 | 148,133.00 |
| Sep 30, 2025 | 144,358.00 |
| Jun 30, 2025 | 148,854.00 |
| Mar 31, 2025 | 174,774.00 |
| Dec 31, 2024 | 150,157.00 |
| Sep 30, 2024 | 186,430.00 |
| Jun 30, 2024 | 274,302.00 |
| Mar 31, 2024 | 268,766.00 |
| Dec 31, 2023 | 275,618.00 |
| Sep 30, 2023 | 311,871.00 |
| Jun 30, 2023 | 352,506.00 |
| Mar 31, 2023 | 18,082.00 |
| Dec 31, 2022 | 497,554.00 |
| Sep 30, 2022 | 18,484.00 |
| Jun 30, 2022 | 883,726.00 |
| Mar 31, 2022 | 729,036.00 |
| Dec 31, 2021 | 3.48 Mn |
| Sep 30, 2021 | 11,595.00 |
| Jun 30, 2021 | 910,702.00 |